RS50939B - 2-fenil benzimidazoli i imidazo-/4,5/-piridini kao cdsi/chk2 -inhibitori i pomoćna sredstva u hemoterapiji ili terapiji zračenja pri lečenju kancera - Google Patents

2-fenil benzimidazoli i imidazo-/4,5/-piridini kao cdsi/chk2 -inhibitori i pomoćna sredstva u hemoterapiji ili terapiji zračenja pri lečenju kancera

Info

Publication number
RS50939B
RS50939B YUP-492/03A YUP49203A RS50939B RS 50939 B RS50939 B RS 50939B YU P49203 A YUP49203 A YU P49203A RS 50939 B RS50939 B RS 50939B
Authority
RS
Serbia
Prior art keywords
pyridines
imidazo
chemotherapy
adjuvants
inhibitors
Prior art date
Application number
YUP-492/03A
Other languages
English (en)
Inventor
Kristen L. Arienti
Frank U. Axe
J. Guy Breitenbucher
Liming Huang
Alice Lee
Kelly J. Mcclure
Original Assignee
Ortho-Mcneil Pharmaceutical Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho-Mcneil Pharmaceutical Inc. filed Critical Ortho-Mcneil Pharmaceutical Inc.
Publication of YU49203A publication Critical patent/YU49203A/sh
Publication of RS50939B publication Critical patent/RS50939B/sr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
YUP-492/03A 2001-10-19 2002-10-18 2-fenil benzimidazoli i imidazo-/4,5/-piridini kao cdsi/chk2 -inhibitori i pomoćna sredstva u hemoterapiji ili terapiji zračenja pri lečenju kancera RS50939B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33030401P 2001-10-19 2001-10-19

Publications (2)

Publication Number Publication Date
YU49203A YU49203A (sh) 2006-05-25
RS50939B true RS50939B (sr) 2010-08-31

Family

ID=23289169

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP-492/03A RS50939B (sr) 2001-10-19 2002-10-18 2-fenil benzimidazoli i imidazo-/4,5/-piridini kao cdsi/chk2 -inhibitori i pomoćna sredstva u hemoterapiji ili terapiji zračenja pri lečenju kancera

Country Status (12)

Country Link
US (2) US7271261B2 (sr)
EP (1) EP1435947B1 (sr)
JP (1) JP4637481B2 (sr)
AT (1) ATE369854T1 (sr)
BR (1) BR0206161A (sr)
CA (1) CA2464000C (sr)
DE (1) DE60221866T2 (sr)
ES (1) ES2292812T3 (sr)
NO (1) NO20032759L (sr)
RS (1) RS50939B (sr)
WO (1) WO2003032984A1 (sr)
ZA (1) ZA200305533B (sr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7884120B2 (en) 2002-08-19 2011-02-08 Lorus Therapeutics Inc. 2,4,5-trisubstituted imidazoles and their use as anti-microbial agents
DE10243027A1 (de) 2002-09-17 2004-03-25 Bayer Ag 2-Phenyl-benzimidazol-5-sulfonsäure aus isolierter 3,4-Diaminobenzol-sulfonsäure sowie deren Verwendung in kosmetischen Zubereitungen
WO2004093873A1 (en) 2003-04-17 2004-11-04 Janssen Pharmaceutica, N.V. 2-phenyl-benzimidazol and 2-phenyl-imidazo-`4,5!-pyridine derivatives as checkpoint kinase cds1 (chk2) inhibitors for the treatment of cancer
US20050078598A1 (en) * 2003-08-21 2005-04-14 Anuj Batra Enhancement to the multi-band OFDM physical layer
AU2004289539C1 (en) * 2003-11-14 2012-06-07 Lorus Therapeutics Inc. Aryl imidazoles and their use as anti-cancer agents
US7250427B2 (en) 2004-06-30 2007-07-31 Janssen Pharmaceutica, N.V. Aryl-substituted benzimidazole and imidazopyridine ethers
KR20060087386A (ko) * 2005-01-28 2006-08-02 주식회사 대웅제약 신규 벤조이미다졸 유도체 및 이를 함유하는 약제학적조성물
WO2006080821A1 (en) * 2005-01-28 2006-08-03 Daewoong Pharmaceutical Co., Ltd. Novel benzoimidazole derivatives and pharmaceutical composition comprising the same
MX2007011234A (es) 2005-03-14 2007-11-12 Transtech Pharma Inc Derivados de benzazol, composiciones y metodos de uso en la forma de inhibidores de b-secretasa.
US8148392B2 (en) 2005-05-25 2012-04-03 Lorus Therapeutics Inc. 2-indolyl imidazo [4,5-d] phenanthroline derivatives and their use in the treatment of cancer
CA2612419C (en) 2005-06-23 2017-06-13 Array Biopharma Inc. Process for preparing benzimidazole compounds
WO2007070173A2 (en) * 2005-10-31 2007-06-21 Merck & Co., Inc. Cetp inhibitors
PL2054405T3 (pl) 2006-07-11 2014-03-31 Dae Woong Pharma Nowe pochodne biarylobenzimidazolu i zawierająca je kompozycja farmaceutyczna
FR2904314A1 (fr) * 2006-07-26 2008-02-01 Centre Nat Rech Scient Composes pyridaziniques et pyrroliques lineaires, procedes d'obtention et applications
PE20080888A1 (es) * 2006-10-18 2008-08-26 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE LA ACIL-TRANSFERASA DE ACIL-CoA-DIACIL-GLICEROL 1 (DGAT1)
UA100684C2 (uk) 2007-03-15 2013-01-25 Новартіс Аг Похідні бензилу та піридинілу як модулятори сигнального шляху hedgehog
MX2010001866A (es) * 2007-08-23 2010-03-11 Sanofi Aventis Derivados de azoloarina, metodo para su produccion, productos farmaceuticos que contienen estos compuestos y su uso.
GB0719644D0 (en) 2007-10-05 2007-11-14 Cancer Rec Tech Ltd Therapeutic compounds and their use
AU2008335880B2 (en) * 2007-12-13 2014-03-13 Siena Biotech S.P.A. Hedgehog pathway antagonists and therapeutic applications thereof
JP2009171854A (ja) * 2008-01-21 2009-08-06 Olympus Corp 細胞洗浄方法および移植物の製造方法
GB0803018D0 (en) 2008-02-19 2008-03-26 Cancer Rec Tech Ltd Therapeutic compounds and their use
US20110021532A1 (en) * 2008-04-22 2011-01-27 Merck Frosst Canada Ltd. Novel substituted heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
EP2424533A4 (en) 2009-04-27 2012-10-17 High Point Pharmaceuticals Llc SUBSTITUTED ISOQUINOLINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR METHODS OF USE AS-SECRETASE INHIBITORS
JP2013522364A (ja) 2010-03-23 2013-06-13 ハイ ポイント ファーマシューティカルズ,リミティド ライアビリティ カンパニー 置換イミダゾ[1,2−b]ピリダジン誘導体、医薬組成物、及びβ−セクレターゼ阻害剤としての使用の方法
US8609672B2 (en) 2010-08-27 2013-12-17 University Of The Pacific Piperazinylpyrimidine analogues as protein kinase inhibitors
US9273347B2 (en) * 2010-09-10 2016-03-01 Bio-Rad Laboratories, Inc. Detection of RNA-interacting regions in DNA
JP5695749B2 (ja) * 2010-09-28 2015-04-08 デーウン ファーマシューティカル カンパニー リミテッド ベンゾイミダゾール誘導体の新規な製造方法
WO2012112606A1 (en) 2011-02-15 2012-08-23 Bio-Rad Laboratories, Inc. Detecting methylati0n in a subpopulation of genomic dna
KR101387970B1 (ko) 2011-04-20 2014-04-25 인제대학교 산학협력단 암 예방 및 치료용 조성물 및 건강기능식품
JP6073910B2 (ja) 2011-11-09 2017-02-01 キャンサー・リサーチ・テクノロジー・リミテッド 5−(ピリジン−2−イル−アミノ)−ピラジン−2−カルボニトリル化合物及びその治療使用
SG11201407238VA (en) 2012-05-15 2014-12-30 Cancer Rec Tech Ltd 5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2-pyridyl]amino]pyrazine-2-carbonitrile and therapeutic uses thereof
AU2014235962A1 (en) 2013-03-20 2015-09-10 Aptose Biosciences Inc. 2-substituted imidazo[4,5-d]phenanthroline derivatives and their use in the treatment of cancer
CN103288803B (zh) * 2013-05-17 2017-10-31 郎恒元 苯并咪唑酰胺类化合物及其制备方法和应用
WO2015051302A1 (en) 2013-10-04 2015-04-09 Aptose Biosciences Inc. Compositions and methods for treating cancers
CN104194778B (zh) * 2014-09-25 2016-03-30 黑龙江大学 磷氧基团修饰n-苯基-苯并咪唑电子传输材料、合成方法及电致磷光器件的制备方法
JP7278945B2 (ja) * 2016-09-20 2023-05-22 サントル レオン ベラール 抗癌剤としてのベンゾイミダゾール誘導体
WO2019089511A1 (en) 2017-10-30 2019-05-09 Aptose Biosciences Inc. Aryl imidazoles for the treatment of cancer
EA202192394A1 (ru) * 2019-04-10 2022-01-24 Селлестия Биотек Аг Ингибиторы пути передачи сигнала notch и их применение для лечения рака

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3346575A1 (de) 1983-12-23 1985-07-04 Dr. Karl Thomae Gmbh, 7950 Biberach Neue benzimidazole, ihre herstellung und diese verbindungen enthaltende arzneimittel
LU85544A1 (fr) 1984-09-19 1986-04-03 Cird Derives heterocycliques aromatiques,leur procede de preparation et leur application dans les domaines therapeutique et cosmetique
DE3522230A1 (de) 1985-06-21 1987-01-02 Thomae Gmbh Dr K Neue 2-arylimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
GB9108279D0 (en) * 1991-04-18 1991-06-05 Ucb Sa A method of preparing 1h-benzimidazoles
US5821258A (en) 1994-12-27 1998-10-13 Mitsui Chemicals, Inc. Phenylbenzimidazole derivatives
US6184235B1 (en) 1996-08-14 2001-02-06 Warner-Lambert Company 2-phenyl benzimidazole derivatives as MCP-1 antagonists
US5942532A (en) 1997-09-05 1999-08-24 Ortho Pharmaceutical Corporation 2-substituted phenyl-benzimidazole antibacterial agents
AU747705C (en) * 1997-12-13 2004-09-23 Bristol-Myers Squibb Company Use of pyrazolo (3,4-b) pyridine as cyclin dependent kinase inhibitors
CA2332989A1 (en) 1998-05-22 1999-12-02 Avanir Pharmaceuticals Benzimidazole derivatives as modulators of ige
ATE284392T1 (de) 1998-11-03 2004-12-15 Abbott Gmbh & Co Kg Substituierte 2-phenylbenzimidazole, deren herstellung und anwendung
GB9914825D0 (en) * 1999-06-24 1999-08-25 Smithkline Beecham Spa Novel compounds
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
GB0007934D0 (en) * 2000-03-31 2000-05-17 Darwin Discovery Ltd Chemical compounds
DE10026435A1 (de) * 2000-05-29 2002-04-18 Osram Opto Semiconductors Gmbh Kalzium-Magnesium-Chlorosilikat-Leuchtstoff und seine Anwendung bei Lumineszenz-Konversions-LED
JP4695819B2 (ja) * 2000-05-29 2011-06-08 パテント−トロイハント−ゲゼルシヤフト フユール エレクトリツシエ グリユーラムペン ミツト ベシユレンクテル ハフツング Ledをベースとする白色発光照明ユニット
ATE350468T1 (de) 2000-06-21 2007-01-15 Chugai Pharmaceutical Co Ltd Cds1-knockout-mäusen und davon abgeleitete zelllinien
US7311858B2 (en) * 2004-08-04 2007-12-25 Intematix Corporation Silicate-based yellow-green phosphors
US20060027785A1 (en) * 2004-08-04 2006-02-09 Intematix Corporation Novel silicate-based yellow-green phosphors
US20060279196A1 (en) * 2005-06-02 2006-12-14 Wei-Jen Hsu White LED
JP2007231250A (ja) * 2006-02-02 2007-09-13 Nichia Chem Ind Ltd 蛍光体及びそれを用いた発光装置

Also Published As

Publication number Publication date
ATE369854T1 (de) 2007-09-15
YU49203A (sh) 2006-05-25
DE60221866D1 (de) 2007-09-27
DE60221866T2 (de) 2008-05-29
US7271261B2 (en) 2007-09-18
ES2292812T3 (es) 2008-03-16
US20080009493A1 (en) 2008-01-10
WO2003032984A8 (en) 2003-11-20
BR0206161A (pt) 2005-02-01
ZA200305533B (en) 2004-10-18
EP1435947B1 (en) 2007-08-15
WO2003032984A1 (en) 2003-04-24
JP2005506349A (ja) 2005-03-03
NO20032759L (no) 2003-08-18
EP1435947A1 (en) 2004-07-14
CA2464000A1 (en) 2003-04-24
US20030176438A1 (en) 2003-09-18
CA2464000C (en) 2011-04-19
NO20032759D0 (no) 2003-06-17
JP4637481B2 (ja) 2011-02-23
US7504414B2 (en) 2009-03-17

Similar Documents

Publication Publication Date Title
RS50939B (sr) 2-fenil benzimidazoli i imidazo-/4,5/-piridini kao cdsi/chk2 -inhibitori i pomoćna sredstva u hemoterapiji ili terapiji zračenja pri lečenju kancera
MY155218A (en) Small molecules useful in the treatment of inflammatory disease
AP1553A (en) Tricyclic inhibitors of poly (ADP-Ribose) polymerases.
MXPA05010819A (es) Uso de antagonistas de opioide perifericos, especialmente metilnaltrexona para tratar sindrome de intestino irritable.
MXPA04001876A (es) Uso de fucanos en el tratamiento de adhesiones, artritis y psoriasis.
MY135766A (en) Quinolinones and naphthyridinones for treating inflammatory diseases
SG145700A1 (en) Pyridyl derivatives and their use as therapeutic agents
MXPA06001134A (es) Inhibidores de la actividad de la proteina cinasa b.
ZA200500908B (en) Ruthenium anticancer complexes
HK1084032A1 (en) Combination therapy of zd6474 with 5-fu and/or cpt-11
EP1178988A4 (en) THERAPEUTIC COMPOUNDS AND METHODS
WO2003106384A3 (en) NOVEL BORIC CHALCONE DERIVATIVES AND USES THEREOF
WO2003039545A3 (en) Carboline derivatives as inhibitors of ikb in the treatment of multiple myeloma and others cancers
YU64602A (sh) Smeša koja se sastoji od kamptotecina i derivata pirimidina za terapiju kancera
DE602005027739D1 (de) Arylsubstituiertes benzimidazol- und imidazopyridinether als wirkstoffe gegen krebs
EP1383516A4 (en) CO-ADMINISTRATION OF A POLYSACCHARIDE WITH A CHEMOTHERAPEUTIC AGENT FOR THE TREATMENT OF CANCER
DE602004006852D1 (de) 2-phenyl-benzimidazol und 2-phenyl-imidazo-4,5ü-pyridin-derivate als checkpoint-kinase-cds1 (chk2)-hemmer zur behandlung von krebs
MXPA04007443A (es) Nuevos compuestos de porfirina-platino solubles en agua con alta selectividad tumoral y su uso para el tratamiento de enfermedades tumorales benignas y malignas.
PL357179A1 (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-mtdc) and/or physiologically compatible salts for treating and/or preventing cancers
HK1074840A1 (en) Novel dithiolopyrrolones with therapeutic activity
HK1079116A1 (en) Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and radiotherapy
MD1569G2 (ro) Metodă de tratament al cancerului mamar în perioada preoperatorie
TR200102557T2 (tr) Tiazonlindolinon bileşikleri.
MXPA03002494A (es) Metodo para reducir toxicidad de quimio terapias combinadas.
AU2002335854A1 (en) 2-phenyl benzimidazoles and imidazo-(4,5)-pyridines as cdsi/chk2-inhibitors and adjuvants to chemotherapy or radiation therapy in the treatment of cancer